Delivering Translational Opportunities From Edinburgh (DTOFE)

Lead Research Organisation: University of Edinburgh

Abstract

Abstracts are not currently available in GtR for all funded research. This is normally because the abstract was not required at the time of proposal submission, but may be because it included sensitive information such as personal details.

Technical Summary

The Confidence in Concept scheme is a key part of MRC’s translational research strategy and provides annual awards to institutions, to be used flexibly to support the earliest stages of multiple translational research projects. The award can be used by the institution to support a number of preliminary-stage translational projects. The projects supported should aim to provide sufficient preliminary data to establish the viability of an approach –– before seeking more substantive funding. It is intended to accelerate the transition from discovery research to translational development projects by supporting preliminary work or feasibility studies to establish the viability of an approach.

Publications

10 25 50
 
Description Career Development Fellowship
Amount £1,500,000 (GBP)
Organisation Cancer Research UK 
Sector Charity/Non Profit
Country United Kingdom
Start 01/2020 
End 01/2026
 
Description EU funded grant with Gdansk (PFK1 CIC6)
Amount £120,000 (GBP)
Organisation University of Gdansk 
Sector Academic/University
Country Poland
Start  
 
Description IAA: Glocal Therapy
Amount £29,000 (GBP)
Organisation Engineering and Physical Sciences Research Council (EPSRC) 
Sector Public
Country United Kingdom
Start 07/2018 
End 05/2019
 
Description MRC Proximity to Discovery
Amount £2,700 (GBP)
Organisation Medical Research Council (MRC) 
Sector Public
Country United Kingdom
Start 09/2018 
End 09/2018
 
Description Proximity to Discovery
Amount £1,300 (GBP)
Organisation Medical Research Council (MRC) 
Sector Public
Country United Kingdom
Start 10/2019 
End 10/2019
 
Description Targeting biological vulnerabilities of glioblastoma (Brain Tumour Awards)
Amount £5,600,000 (GBP)
Funding ID C25858/A28592 
Organisation Cancer Research UK 
Sector Charity/Non Profit
Country United Kingdom
Start 10/2019 
End 09/2024
 
Description Wellcome Trust ITPA
Amount £13,845 (GBP)
Organisation Wellcome Trust 
Sector Charity/Non Profit
Country United Kingdom
Start 10/2018 
End 02/2020
 
Title Developed scale up synthesis of prodrug 
Description We developed the scale-up synthesis of the prodrug GlocaFUR. Approx. 90 g of compound was synthesized in our lab, with > 99% purity, which will enormously simplify prodrug production for forthcoming preclinical studies in larger animals. 
Type Of Material Technology assay or reagent 
Year Produced 2019 
Provided To Others? No  
Impact Potential spin out route once the in vivo efficacy data is evaluated 
 
Title Development of mouse model using CT26 cell lines (Pollard J) 
Description We developed a fast in vivo mouse model using CT26 cell lines injected subcutaneosly in the flank of the animal; this cancer model will be extensively used to test our anti-TAM targeting antibodies in combination with immunotherapy. We were able to define a precise protocol for the lentiviral transduction of iPS cells and we identified several screening candidates for our planned screening using iPS macrophages. We made a significant progress with the development of the human antigen specific T cell killing assay by characterizing the cancer cell T2, by defining a precise protocol for antigen specific killing. 
Type Of Material Model of mechanisms or symptoms - mammalian in vivo 
Year Produced 2019 
Provided To Others? No  
Impact Spin-out resulted from research - awaiting term sheet from Investors 
 
Title Development of new mass spec imaging platform for liver tissue lipidomic analysis 
Description Development of new mass spectrometric imaging platform for liver tissue lipidomic analysis/PK-PD in collaboration with Professor Ruth Andrew. This technology looks promising and data has been selected for presentation at two conferences. It may also be leveraged to support a nascent collaboration with Dr Bansal's group at the University of Twente 
Type Of Material Physiological assessment or outcome measure 
Year Produced 2019 
Provided To Others? Yes  
Impact No impact to report to date 
 
Title Development of well characterised phenotypic assays 
Description Development of a suite of well characterised phenotypic assays (proliferation, alpha-smooth muscle actin differentiation, extracellular matrix deposition) in primary human liver, lung and skin fibroblasts for screening of anti-fibrotic medicines. These assays have already been applied in other projects in collaboration with other researchers (e.g. Ramachandran/Henderson group in Edinburgh). Data included in recent Nature paper. 
Type Of Material Technology assay or reagent 
Year Produced 2019 
Provided To Others? Yes  
Impact Unknown at this time 
 
Title In vivo mouse model using CT26 cell lines 
Description We developed a fast in vivo mouse model using CT26 cell lines injected subcutaneosly in the flank of the animal; this cancer model will be extensively used to test our anti-TAM targeting antibodies in combination with immunotherapy. We were able to define a precise protocol for the lentiviral transduction of iPS cells and we identified several screening candidates for our planned screening using iPS macrophages. We made a significant progress with the development of the human antigen specific T cell killing assay by characterizing the cancer cell T2, by defining a precise protocol for antigen specific killing. 
Type Of Material Cell line 
Year Produced 2018 
Provided To Others? No  
Impact No impact to date. Start up created and seeking investment. 
 
Title Platereader technology 
Description A novel plate-reading platform to study spectral autofluorescence characteristics of catataract has been develop and is available at the MRC Centre for Regenerative medicine. This a bespoke instrumentation with no commercial equivalent that can collect spectral autofluorescent signature with great sensitivity in a wideband spectral range (between 310nm and 550nm). In addition to cataract diagnostics this research tool may be useful to study protein folding and unfolding in age related diseases. molecular diagnostic tool for aging. 
Type Of Material Physiological assessment or outcome measure 
Year Produced 2019 
Provided To Others? No  
Impact In addition to cataract diagnostics this research tool may be useful to study protein folding and unfolding in age related diseases i.e. a novel molecular diagnostic tool for aging. There is no commercial equivalent that can collect spectral autofluorescent signature with great sensitivity in a wideband spectral range 
 
Title Two new model of cholangiocarcinoma harbouring mutational profiles found in human cancer developed 
Description We have developed two new models of cholangiocarcinoma harbouring mutational profiles found in human cancer (NF2 and PlexinB2). The details of these models will be submitted for publication and plasmids and vectors generated for this model will be made available. 
Type Of Material Model of mechanisms or symptoms - human 
Year Produced 2019 
Provided To Others? No  
Impact Details of model haven't been submitted yet. 
 
Description Catholic University of Louvain 
Organisation Catholic University of Louvain
Country Belgium 
Sector Academic/University 
PI Contribution Provided discovery science and project plan.
Collaborator Contribution We established a collaboration with Prof. Pierre van der Bruggen, Louvain, who provided Melan-Mart-1 specific human CD8+ T cells to be used in the T cell killing assay.
Impact No outcomes to date other than experiment results - seeking investment for start up company.
Start Year 2018
 
Description GSK (Mole) 
Organisation GlaxoSmithKline (GSK)
Country Global 
Sector Private 
PI Contribution underpinning science on project
Collaborator Contribution GSK providing external advice
Impact no outputs to date
Start Year 2019
 
Description Max Planck Institute for Evolutionary Anthropology 
Organisation Max Planck Society
Department Max Planck Institute for Evolutionary Anthropology
Country Germany 
Sector Academic/University 
PI Contribution Provided discovery research and project plan
Collaborator Contribution We were able to get a unique plasmid from Dr. Dirk Hoffman which will be used to generate customized lentiviral particles for iPS targeting.
Impact No outputs to date - seeking investment for start up company
Start Year 2018
 
Description Partnership with Isochemix (Mole) 
Organisation IsoChemiX
Country United Kingdom 
Sector Private 
PI Contribution Underpinning science on project
Collaborator Contribution Expertise and partnering for grant applications (SME)
Impact No outputs to report to date
Start Year 2019
 
Description SCRM collaboration 
Organisation UK Regenerative Medicine Platform
Department Scottish Centre for Regenerative Medicine (lead), University of Edinburgh
Country United Kingdom 
Sector Academic/University 
PI Contribution Provided discovery science and project plan - inter-College collaboration
Collaborator Contribution We collaborated with Prof. Lesley Forrester at SCRM who provided us with the iPS human line used to generate iPS-derived macrophages.
Impact No outputs - seeking investment for start up company
Start Year 2018
 
Description Tavec Pharma 
Organisation Tavec Pharma
Country Canada 
Sector Private 
PI Contribution Test one of their therapeutics in this model and other in-vivo cancel models in PI lab.
Collaborator Contribution Providing therapeutic
Impact New collaboration so no outcomes recorded to date
Start Year 2019
 
Description University of Dundee 
Organisation University of Dundee
Country United Kingdom 
Sector Academic/University 
PI Contribution Provided discovery science and project plan
Collaborator Contribution This grant allowed us to establish a collaboration with Prof. Paul Crocker, University of Dundee, who provided us with neutralizing antibodies against one of the identified TAM targets. We used these antibodies to further validate the in vivo fast tumor model using the CT26 cell line.
Impact Outputs from experiment results - seeking investment for company start up.
Start Year 2019
 
Description Interest from two clinical oncologists at UCL and The Christie 
Form Of Engagement Activity A formal working group, expert panel or dialogue
Part Of Official Scheme? No
Geographic Reach National
Primary Audience Professional Practitioners
Results and Impact Our generation of NF2 mutant cholangiocarcinoma is of interest to two clinical oncologists at UCL and The Christie, Manchester who are interested in precision medicine for cholangiocarcinoma. We are now working with these groups to determine whether there are specific therapeutics that are in trial that could be more effective in NF2 mutant cancer.
Year(s) Of Engagement Activity 2019
 
Description Radio interview (Unciti-Broceta) 
Form Of Engagement Activity A broadcast e.g. TV/radio/film/podcast (other than news/press)
Part Of Official Scheme? No
Geographic Reach National
Primary Audience Media (as a channel to the public)
Results and Impact Academic discussed his research in radio interviews in Spain
Year(s) Of Engagement Activity 2019